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Summary of the Application for the Award of Doctor of 
Medicine 
I hereby submit a body of original research for consideration of the award of Doctor of Medicine from the 
University of Adelaide. This is a collection of published original research that has made substantial 
contributions to the modern diagnosis and management of breast cancer. The publications have been 
presented in three clusters, each of which represents one facet of the modern approach to the diagnosis 
and management of breast cancer. 
The first section presents my publications on the theme of population based for 
the early detection of breast cancer. Broadly, the research focus in these publications is on the evaluation 
of existing methods of assessment of screen-detected breast lesions in order to improve diagnostic 
accuracy and limit the morbidity associated with mammographic screening. The clinical value of these 
contributions has been demonstrated independently since this body of work has informed many of the 
algorithms and protocols used by the South Australian breast cancer screening program. In addition. the 
protocols have been adopted for use outside of the screening setting into the wider diagnostic arena. The 
clinical endorsement of my research contributions is a significant acknowledgement of their practical value. 
The middle group of publications describe my contributions towards the evolving rQle of sentinel node. 
biopsy as an alternative to axillary clearance for the staging of breast cancer. This area is of particular 
cogent to our setting. since a large proportion of screen-detected breast cancers, approximately 80%, are 
node negative . Thus, avoidance of the morbidity of axillary clearance while still achieving accurate axillary 
staging is of enormous appeal to our patients. 
My pioneering work in devising and evaluating protocols for the pathologic examination of sentinel nodes 
has informed the recommendations of the NHMRC sponsored SNAC (Sentinel Node versus Axillary 
Clearance) randomised trial. Consequently, these protocols have been used extensively and even outside 
of the trial setting, most pathology laboratories utilise similar assessment protocols as was recommended 
in SNAC. Furthermore, the United Kingdom's recommendations for the pathology examination of sentinel • 
nodes have drawn on our research. 
After validating the concept of SNs in breast cancer, many of the clinically important questions emerging in 
this field have been addressed by our team. For example, my work on intra-operative imprint cytology was 
a conclusive demonstration of the value and limitations of this technique for one stage axillary surgery. In 
the light of our findings intra-operative assessment of sentinel nodes has been expanded to many centres 
and is endorsed by the SNAC trial. 
In the third section of this thesis, my contributions to the rapidly evolving field of molecular and genetics of 
breast cancer are highlighted . Through the Australian HER2 Advisory Board, we have led the evaluation 
and roll out of alternative platforms for HER2 testing and in developing algorithms for the efficient use of 
resources. We have devised national testing algorithms in both settings of metastatic and early breast 
cancer. These algorithms have since been utilised by the international HER2 testing bodies. In a further 
bold initiative, our group pioneered the move to the national adoption of bright field In situ hybridization as 
the first line testing platform for all newly diagnosed breast cancers throughout Australia. This ambitious 
undertaking entailed design and implementation of a nation-wide program of training. certification. quality 
assurance and evaluation. It has been deployed successfully and under my leadership. our laboratory was 
one of only four laboratories in Australia to commence this test in October 2006. 
Similarly. in the area of the genetics of breast cancer, my interest in this field and membership of the 
pathology subcommittee of KCONFAB has provided opportunities to contribute to significant new 
knowledge that illustrate the role of pathology in identification of mutation associated breast cancers. 
Under my leadership, our multi-centre studies have provided cogent arguments in favour of the inclusion of 
the histopathologic and immunophenotypic characteristics of breast cancers in the triage of patients for 
genetic testing. These results were published in pre-eminent pathology journals and have been referred to 
at major scientific conferences. Plans are afoot for the future extensions of this work. 
I am committed to utilising my expertise for the proviSion of high quality diagnostic services as part of a 
multi-disciplinary team involved in the treatment of women with breast diseases. I believe an evidence­
based approach is central to achieving continuous improvements in these efforts. I am persuaded that 
there is substantial evidence demonstrating the value of population based mammographic screening in 
interrupting the natural history of breast cancer and reducing mortality from this disease. I am grateful to 
have the opportunity to contribute to the provision of this care. 
